DCISionRT® Demonstrates 40 Percent Change in Radiation Therapy Treatment Recommendation for DCIS Patients
- Thursday, December 2, 2021, 7:10
- Business
- Add a comment
LAGUNA HILLS, Calif., Dec. 2, 2021 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today it will be presenting new data on its ongoing prospective PREDICT study of DCIS patients at the 2021…
About the Author
adminasapcorp has written 41283 stories on this site.